Keeping insulin low by fasting around your dose ensures your body can respond properly and gives you the most bang for your buck
A large retrospective cohort study from Weill Cornell Medical College - examining 255 patients (92% women, mean age 64) with DXA scans before and after starting semaglutide or tirzepatide - found that GLP-1 receptor agonist use was associated with greater annualized total hip bone loss in patients without diabetes, while patients with diabetes showed bone loss more comparable to non-users
Fifty-eight percent were male, 71% were White, 7% were Black or African American and 13% were Hispanic
The practical upshot is that the two headline effects should be tracked as distinct outcomes, not bundled
Available from: Yang M, Hu X, Xie L, Zhang L, Zhou J, Lin J, et al